Latest Breaking News On - வாத நோய் கூட்டணி - Page 1 : comparemela.com

Nearly 30% of those with rheumatic disease saw employment change early in COVID-19 pandemic

Nearly 30% of those with rheumatic disease saw employment change early in COVID-19 pandemic
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesJonathans hausmannGlobal rheumatology allianceBeth israel deaconess medical centerAmerican college of rheumatologyAmerican collegeRheumatology allianceRheumatology alliance surveyLatin americanNative americanஒன்றுபட்டது மாநிலங்களில்ஜொனாதன்கள் ஹவுஸ்மேன்உலகளாவிய வாத நோய் கூட்டணிபெத் இஸ்ரேல் டேப்ககோணேஸ் மருத்துவ மையம்அமெரிக்கன் கல்லூரி ஆஃப் வாத நோய்அமெரிக்கன் கல்லூரி

Baseline medication use is associated with COVID-19 severity in people with rheumatic diseases

Baseline medication use is associated with COVID-19 severity in people with rheumatic diseases
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Zachary wallaceGlobal rheumatology allianceRheumatology allianceJeffrey sparksசக்கரி வாலஸ்உலகளாவிய வாத நோய் கூட்டணிவாத நோய் கூட்டணிஜெஃப்ரி தீப்பொறிகள்

Rituximab a Hazard in RA Patients With COVID

email article Patients with rheumatoid arthritis (RA) treated with rituximab (Rituxan) or JAK inhibitors had more severe COVID-19 disease courses, analysis of data from a large registry found. In an adjusted multivariate analysis compared with patients on tumor necrosis factor (TNF) inhibitors, those on rituximab had a fourfold higher risk for worse disease (OR 4.15, 95% CI 3.16-5.44), while those on JAK inhibitors had a twofold greater risk (OR 2.06, 95% CI 1.60-2.65), reported Jeffrey Sparks, MD, of Harvard Medical School in Boston, at the European League Against Rheumatism virtual congress. As we all know, there has been intense interest during the pandemic in repurposing immune modulating drugs for COVID-19 treatment, he said.

United statesNancy walshGlobal rheumatology allianceRegina college in newportHarvard medical schoolPeuropean league against rheumatismJeffrey sparksRheumatology allianceSalve regina collegeLeague againstTumor necrosis factorCovid 19ஒன்றுபட்டது மாநிலங்களில்நான்சி வால்ஷ்உலகளாவிய வாத நோய் கூட்டணிரெஜினா கல்லூரி இல் நியூபோர்ட்

Immunosuppressants and COVID-19

Immunosuppressants and COVID-19 Immunosuppressant drugs are currently being trialled as a potential COVID-19 treatment. Credit: Shidlovski / iStock / Getty Images Plus Immunosuppressant drugs commonly used for autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease, might, in principle, increase the risk of severe COVID-19 infection and lower vaccines’ efficacy. Common cold and other upper respiratory tract infections, for example, can be more common in people taking immunosuppressants. Yet, some such drugs – glucocorticoids, anti-tumour necrosis factors (anti-TNF) and disease-modifying antirheumatic drugs (DMARDs) – are being trialled as potential COVID-19 therapeutics. Why does this conflicting dichotomy exist? The answer may lie in the difference between the chronic and acute use of these drugs.

Catherine hillAustralian rheumatology associationGlobal rheumatology allianceRheumatics diseasesRheumatology allianceProfessor catherine hillAustralian rheumatologyகேத்தரின் மலைஆஸ்திரேலிய வாத நோய் சங்கம்உலகளாவிய வாத நோய் கூட்டணிவாத நோய் கூட்டணிப்ரொஃபெஸர் கேத்தரின் மலைஆஸ்திரேலிய வாத நோய்

COVID Death: Which Rheumatic Patients Are at Risk?

Mortality raised among those who were older, male, and had higher disease activity

United statesPedrom machadoUniversity college londonGlobal rheumatology allianceRheumatology allianceCo vidCovid 19Rheumatoid arthritisConnective tissueஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் கல்லூரி லண்டன்உலகளாவிய வாத நோய் கூட்டணிவாத நோய் கூட்டணிஇணை வித்முடக்கு கீல்வாதம்இணைப்பு திசு